Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension study of brazikumab in moderate to severe active ulcerative colitis
MOH_2021-11-04_010375Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of brazikumab in autoimmune colitis (2 arms), sponsored by AstraZeneca. Primary endpoint: Long-term safety of brazikumab. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
brazikumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2021-11-04_010375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-04_010375.